Telomir-1 reverses insulin resistance to near pre-diabetes in zebrafish T2D study

Telomir Pharmaceuticals, Inc.

Telomir-1 restored glucose homeostasis, reducing HOMA-IR values and improving oral glucose tolerance in zebrafish model.
Dose-dependent normalization of blood glucose levels observed; insulin resistance reversed to near pre-diabetes levels.
Novel mechanism targets iron metabolism to address oxidative stress and beta-cell damage, root causes of Type 2 diabetes.
Treated models showed increased survival rates, reinforcing therapeutic potential of Telomir-1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.